Project Grant R15HL159599
Award Date
9/1/22
Completion Date
8/31/25
Dollars Obligated
$866K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $564,445 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of Texas Health Science Center at Houston (UTHealth). The 7-year award, spanning March 2025 to December 2031, will support UTHealth's "Hypoxia-Inflammation Program" focused on targeting hypoxia-inducible factors (HIFs) for heart and lung disease. The program incorporates three complementary research projects that build...
This $847,164 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the underlying mechanisms of pathologic remodeling of Purkinje cells in the ventricular conduction system. The research aims to provide a deep mechanistic understanding of how paracrine signaling from activated fibroblasts may drive Purkinje cell transcriptional remodeling, leading to repression of rapid...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $1,283,558 to the Massachusetts Institute of Technology (MIT) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The purpose of this 4-year grant, with a start date of August 1, 2024, is to develop and demonstrate the concept of Multi-Electroplasmonic Nanoantenna Arrays (MENAS) - a breakthrough wireless technology for high-resolution, intracellular electrophysiological recording of...
This $741,890 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the use of biomimetic nanomaterials for immunomodulation of the cardiosplenic axis following myocardial infarction. The research will explore mechanisms by which targeted delivery of HDAC inhibitors to the spleen can produce therapeutic effects in the heart post-MI, with a focus on understanding the role of different...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $655,636 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Texas Heart Institute (THI) to investigate the role of cardiac fibroblasts in single ventricle congenital heart disease (CVD) progression to heart failure. The research aims to gain insights into the intrinsic molecular mechanisms, metabolic remodeling, and deleterious signaling of CVD cardiac fibroblasts that contribute to the development of heart...
This $2,304,645 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837) supports research to develop cardiac-targeted lipid nanoparticles (CLNPs) for delivering therapeutic nucleic acids to treat contractile disorders in the heart. The research aims to: 1) characterize the efficacy and safety of CLNPs with different inhibitory cargos (siRNA, shRNA, antisense oligonucleotides) targeting...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $249,000 Project Grant to the University of Arkansas to develop microphysiological systems that can precisely control oxygen levels and monitor the effects on cardiomyocyte function. The goal is to gain a comprehensive understanding of the molecular pathways activated and the resulting impacts on cardiomyocyte behavior in response to hypoxic cardiac injury, such as...
This $1,245,515.38 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of cell metabolism and epigenetics in the transdifferentiation of fibroblasts into endothelial cells for vascular regeneration. The awardee, The Methodist Hospital Research Institute (HMRI), will conduct in vivo experiments in mice to investigate how metabolic regulation influences DNA accessibility and...
This $771,750 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research investigating the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The primary research objectives are to: Determine how cardiac macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and decrease NAD pools, which are critical for cardiac muscle energetics....
This $153,512 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate how changes in the mechanical properties of cardiac tissue, specifically elasticity and viscosity, impact the signaling between macrophages and fibroblasts in the progression of cardiac fibrosis. The research will utilize an engineered cell culture system to study these biomechanical factors and their...